** Shares of Inhalerx surge as much as 127.3% to A$0.050, their biggest pct gain since March 2020
** Medical device maker to get up to A$38.5 mln ($25.81 mln) in funds from Clendon Biotech Capital to cover clinical trial costs
** Stock hits its highest level since late March
** Around 3.7 mln shares change hands, 72.3x the 30-day avg
** Stock up 34.5% YTD, including current session, as at 0140 GMT
($1 = 1.4916 Australian dollars)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.